Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune ...
Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA ...
Repurposing avoids the long, sometimes multi-decade process of developing and approving a new drug for a specific indication, ...
The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider ...
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new ...
PathAI makes AI models that help with the analysis of patient tissue samples and diagnostic tools. Roche has partnered with ...
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech ...
While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug ...
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by ...
The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, ...
The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results